Vincent Marconi is an Infectious Disease physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1670 Clairmont Rd
Decatur, GA 300334004
Telephone
404-321-6111Registry record last updated 3 Sept 2015.
Clinical trials
- Baricitinib Curative Repression of HIV-1
Sponsor: Emory University
- Functional Interval Training for Veterans Exercising Through Telehealth.
Sponsor: VA Office of Research and Development
- Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System
Sponsor: Atlanta VA Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
49.1%Nonsteroidal Anti-inflammatory Drug26.3%Ibuprofen100%Part D<11 patientsSSRI22.8%Trazodone Hcl100%Part D<11 patientsCardiovascular
28.1%Statin28.1%Rosuvastatin Calcium100%Part D<11 patientsAnti-infectives
22.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.8%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
Emory University
FY2026$619,562R01MH128158 - Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
Emory University
FY2025$638,381R01MH128158 - Host Genetic and Epigenetic Factors of the Progression, Comorbidities and Outcomes of Viral Infection
Veterans Health Administration
FY2025I01BX006008
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”